News Search Results
Jan 14, 2026, 09:00 ET High School Students Nationwide Kick off Philanthropic Competition to Help All Blood Cancer Patients Live Longer, Better Lives
founding in 1949, it has consistently evolved to better serve people affected by all 100-plus types of blood cancers—including leukemia, lymphoma, myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms. Blood Cancer United offers free, trustworthy resources, personalized support,
More news about: BLOOD CANCER UNITED, INC.
Jan 13, 2026, 12:33 ET Adimab Records Another Year of Double-Digit Clinical Program Growth
dyslipidemia.IASO Bio's FUCASO® (equecabtagene autoleucel), a BCMA CAR-T program approved in China for the treatment of patients with multiple myeloma.Invivyd's PEMGARDA™ (pemivibart), a SARS-CoV-2 monoclonal antibody authorized for prophylactic emergency use in the United States to prevent
More news about: Adimab, LLC
Jan 13, 2026, 08:15 ET ACS Annual Statistics Report: Milestone 70 Percent 5-Year Survival Rate for all Cancers Combined; Largest Gains for Advanced and Fatal Cancers
during 2015-2021 in the United States. Survival gains since the mid-1990s are especially notable for people diagnosed with more fatal cancers, such as myeloma (from 32% to 62%), liver cancer (7% to 22%), and lung cancer (15% to 28%). These important findings are published today in
More news about: American Cancer Society
Jan 12, 2026, 08:05 ET CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors
patients suffering from solid tumors. Zevor-cel is approved by the National Medical Products Administration (NMPA) in China for the treatment of multiple myeloma."CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies," said Zonghai Li,
More news about: CARsgen Therapeutics
Jan 12, 2026, 07:00 ET Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
Key Program Highlights in 2025Selinexor in Multiple Myeloma Demand for XPOVIO was consistent in 2025 versus 2024 in the increasingly competitive multiple myeloma marketplace, with the community setting continuing to drive approximately 60% of overall
More news about: Karyopharm Therapeutics Inc.
Jan 06, 2026, 03:19 ET Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report
Squibb | Multiple myelomaMezigdomide, a second-generation CELMoD therapy administered orally to treat relapsed or refractory multiple myeloma, is designed to degrade Ikaros and Aiolos, key transcription factors in hematopoietic cell development, producing both anti-myeloma and immune-stimulatory
More news about: Clarivate Plc
Jan 06, 2026, 03:07 ET Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report
Squibb | Multiple myelomaMezigdomide, a second-generation CELMoD therapy administered orally to treat relapsed or refractory multiple myeloma, is designed to degrade Ikaros and Aiolos, key transcription factors in hematopoietic cell development, producing both anti-myeloma and immune-stimulatory
More news about: Clarivate Plc
Jan 02, 2026, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please
More news about: Karyopharm Therapeutics Inc.
Dec 28, 2025, 19:10 ET CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596
product, CT0596. The applications seek to initiate two corresponding Phase Ib/Ⅱ clinical trials for the treatment of relapsed/refractory multiple myeloma (R/R MM) and primary plasma cell leukemia (pPCL), respectively.
More news about: CARsgen Therapeutics
Dec 19, 2025, 07:44 ET Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030
with longer follow up," said Robert Orlowski, M.D., Ph.D., Deputy Chair, Professor of Medicine, and Director of Translational Myeloma Research in the Departments of Lymphoma/Myeloma and Experimental Therapeutics at The University of Texas MD Anderson Cancer Center and the lead investigator for the
More news about: USA News Group
Dec 16, 2025, 20:00 ET Antengene Expands XPOVIO® Indications in Malaysia with Approval in Diffuse Large B-cell Lymphoma
XPOVIO® has further expanded its portfolio of approved indications in Malaysia, bringing the total to three indications across multiple myeloma (MM) and DLBCL, two major therapeutic areas in hematology. Prior to this, XPOVIO® was approved in Malaysia for two indications, including
More news about: Antengene Corporation Limited
Dec 16, 2025, 08:00 ET Utah Cancer Specialists Partners with Canopy for Remote Therapeutic Monitoring and Enterprise AI
Parrinello, C. M., & Ascha, M. S. (2024, December 9). Electronic patient-reported outcome (ePRO) symptom monitoring for relapsed/refractory multiple myeloma in community settings, focusing on bispecific antibody therapy. American Society of Hematology Annual Meeting6 Canopy internal analysis
More news about: Canopy
Dec 11, 2025, 17:31 ET Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight
Vaccine Safety in Daratumumab-Treated Myeloma PatientsNew research presented at ASH 2025 addressed an important question regarding vaccine safety in multiple myeloma patients receiving immunosuppressive therapy. A clinical trial of 41 patients with multiple myeloma who had undergone autologous stem-cell
More news about: DelveInsight Business Research, LLP
Dec 09, 2025, 08:00 ET Oral Presentation at ASH 2025 Shows Canopy RTM Cuts Infection-Related Hospitalizations by 52% and Generates Nearly $1M in Annual Savings per 1,000 Patients
Parrinello, C. M., & Ascha, M. S. (2024, December 9). Electronic patient-reported outcome (ePRO) symptom monitoring for relapsed/refractory multiple myeloma in community settings, focusing on bispecific antibody therapy. American Society of Hematology Annual Meeting4 Kolodziej, M. A.,
More news about: Canopy
Dec 09, 2025, 07:44 ET Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
www.DARZALEX.com.About Multiple MyelomaMultiple myeloma is an incurable blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow.7 In multiple myeloma, these plasma cells proliferate and spread rapidly and
More news about: Johnson & Johnson
Dec 09, 2025, 07:30 ET Tec-Dara Combination Offers Substantial Improvement Over Standard Second-Line Therapies for Relapsed or Refractory Multiple Myeloma
with relapsed/refractory Multiple Myeloma (RRMM): Results of MajesTEC-3ORLANDO, Fla., Dec. 9, 2025 /PRNewswire/ -- Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab,
More news about: American Society of Hematology
Dec 08, 2025, 13:41 ET Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
hematologic cancer, in the United States, Europe, and other global regions. In addition, Stemline commercializes selinexor, an XPO1 inhibitor for multiple myeloma, in Europe. The company is also conducting multiple label-expansion studies with elacestrant and tagraxofusp in breast and hematologic cancer indications,
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 13:30 ET Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
hematologic cancer, in the United States, Europe, and other global regions. In addition, Stemline commercializes selinexor, an XPO1 inhibitor for multiple myeloma, in Europe. The company is also conducting multiple label-expansion studies with elacestrant and tagraxofusp in breast and hematologic cancer indications,
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 07:00 ET Karyopharm to Participate in Baird's Biotech Discovery Series
Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please
More news about: Karyopharm Therapeutics Inc.
Dec 07, 2025, 21:08 ET CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
relapsed/refractory multiple myeloma (R/R MM) was presented in a poster at the 67th American Society of Hematology (ASH) Annual Meeting. The poster was titled "A First-in-Human Study of CT0596, an Allogeneic CAR T-Cell Therapy Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma." The publication
More news about: CARsgen Therapeutics
Dec 07, 2025, 21:00 ET Median PFS Trending Beyond One Year: Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting
multiple myeloma (RRMM) in China. According to Frost & Sullivan, as of November 2024, LBL-034 is the second most clinically advanced GPRC5D-targeted CD3 T-cell engager globally. In October 2024, LBL-034 received Orphan Drug Designation (ODD) from the U.S. FDA for the treatment of multiple myeloma.About
More news about: Leads Biolabs
Dec 07, 2025, 20:57 ET IASO Bio Presents Updated Results for Equecabtagene Autoleucel in High-Risk Newly Diagnosed Multiple Myeloma Patients at 2025 ASH
therapy product, Equecabtagene Autoleucel (Eque-cel), for the treatment of transplant-ineligible patients with high-risk newly diagnosed multiple myeloma (NDMM) at the 2025 American Society of Hematology (ASH) Annual Meeting. The data demonstrate that Eque-cel can provide deep and durable responses while
More news about: IASO Bio
Dec 07, 2025, 20:02 ET ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
R/R MM patients who had failed ≥2 lines of previous anti-myeloma therapies that included at least a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 mAb; and must be relapsed or refractory to their last anti-myeloma regimen. Prior BCMA- or GPRC5D-targeting therapy was allowed.IBI3003
More news about: Innovent Biologics
Dec 07, 2025, 19:15 ET CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
multiple myeloma (R/R MM) was presented in a poster at the 67th American Society of Hematology (ASH) Annual Meeting. The poster was titled "A First-in-Human Study of CT0596, an Allogeneic CAR T-Cell Therapy Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma." The
More news about: CARsgen Therapeutics
Dec 07, 2025, 08:00 ET Orna Therapeutics Presents New Data Supporting its in vivo CAR Programs for Autoimmune Diseases and Oncology at the 67th American Society of Hematology Annual Meeting
Treatment of Multiple MyelomaIn today's poster presentation, Orna will showcase preclinical data demonstrating the potential of its in vivo panCARTM therapy to treat a range of plasma cell or BCMA-related diseases including multiple myeloma.Key findings in the
More news about: Orna Therapeutics